-
1
-
-
2342552056
-
Prognostic molecular markers in early breast cancer
-
DOI 10.1186/bcr777
-
Esteva FJ, Hortobagyi GN., Prognostic molecular markers in early breast cancer. Breast Cancer Res. 2004; 6: 109-118. (Pubitemid 38607664)
-
(2004)
Breast Cancer Research
, vol.6
, Issue.3
, pp. 109-118
-
-
Esteva, F.J.1
Hortobagyi, G.N.2
-
2
-
-
37249004281
-
Predictive markers in breast cancer - The present
-
DOI 10.1111/j.1365-2559.2007.02897.x
-
Payne SJ, Bowen RL, Jones JL, Wells CA., Predictive markers in breast cancerâthe present. Histopathology. 2008; 52: 82-90. (Pubitemid 350265187)
-
(2008)
Histopathology
, vol.52
, Issue.1
, pp. 82-90
-
-
Payne, S.J.L.1
Bowen, R.L.2
Jones, J.L.3
Wells, C.A.4
-
3
-
-
18844421831
-
Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma
-
DOI 10.1002/cncr.21030
-
Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI., Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer. 2005; 103: 2241-2251. (Pubitemid 40686567)
-
(2005)
Cancer
, vol.103
, Issue.11
, pp. 2241-2251
-
-
Grann, V.R.1
Troxel, A.B.2
Zojwalla, N.J.3
Jacobson, J.S.4
Hershman, D.5
Neugut, A.I.6
-
4
-
-
19344364880
-
Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
-
Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687-1717.
-
(2005)
Lancet.
, vol.365
, pp. 1687-1717
-
-
-
5
-
-
0000719778
-
Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials
-
Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998; 351: 1451-1467.
-
(1998)
Lancet.
, vol.351
, pp. 1451-1467
-
-
-
6
-
-
0032423729
-
Steroid hormone receptors in breast cancer management
-
DOI 10.1023/A:1006132427948
-
Osborne CK., Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat. 1998; 51: 227-238. (Pubitemid 29054556)
-
(1998)
Breast Cancer Research and Treatment
, vol.51
, Issue.3
, pp. 227-238
-
-
Osborne, C.K.1
-
7
-
-
79953778669
-
-
NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2009. Fort Washington, PA: National Comprehensive Cancer Network.
-
NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2009. Fort Washington, PA: National Comprehensive Cancer Network; 2009.
-
(2009)
-
-
-
8
-
-
64949128193
-
Early breast cancer
-
Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC., Early breast cancer. Lancet. 2009; 373: 1463-1479.
-
(2009)
Lancet.
, vol.373
, pp. 1463-1479
-
-
Benson, J.R.1
Jatoi, I.2
Keisch, M.3
Esteva, F.J.4
Makris, A.5
Jordan, V.C.6
-
9
-
-
42549116694
-
Current issues in ER and HER2 testing by IHC in breast cancer
-
DOI 10.1038/modpathol.2008.34, PII MODPATHOL200834
-
Gown AM., Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008; 21 (suppl 2): S8-S15. (Pubitemid 351592775)
-
(2008)
Modern Pathology
, vol.21
, Issue.SUPPL. 2
-
-
Gown, A.M.1
-
10
-
-
73349119689
-
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller
-
et al.
-
Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009; 27: 5700-5706.
-
(2009)
J Clin Oncol.
, vol.27
, pp. 5700-5706
-
-
Gonzalez-Angulo, A.M.1
Litton, J.K.2
Broglio, K.R.3
-
11
-
-
77955504676
-
Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer
-
et al.
-
Albert JM, Gonzalez-Angulo AM, Guray M, et al. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys. 2010; 77: 1296-1302.
-
(2010)
Int J Radiat Oncol Biol Phys.
, vol.77
, pp. 1296-1302
-
-
Albert, J.M.1
Gonzalez-Angulo, A.M.2
Guray, M.3
-
12
-
-
33845382806
-
Nonparametric estimation from incomplete observations
-
Kaplan EL, Meier P., Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 547-581.
-
(1958)
J Am Stat Assoc.
, vol.53
, pp. 547-581
-
-
Kaplan, E.L.1
Meier, P.2
-
14
-
-
0041328350
-
Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation
-
DOI 10.1016/S0360-3016(03)00593-5
-
Woodward WA, Strom EA, Tucker SL, et al. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2003; 57: 336-344. (Pubitemid 37040928)
-
(2003)
International Journal of Radiation Oncology Biology Physics
, vol.57
, Issue.2
, pp. 336-344
-
-
Woodward, W.A.1
Strom, E.A.2
Tucker, S.L.3
Katz, A.4
McNeese, M.D.5
Perkins, G.H.6
Buzdar, A.U.7
Hortobagyi, G.N.8
Hunt, K.K.9
Sahin, A.10
Meric, F.11
Sneige, N.12
Buchholz, T.A.13
-
15
-
-
0035900920
-
Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes
-
Fisher B, Dignam J, Tan-Chiu E, et al. Prognosis and treatment of patients with breast tumors of 1 centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst. 2001; 93: 112-120. (Pubitemid 32111988)
-
(2001)
Journal of the National Cancer Institute
, vol.93
, Issue.2
, pp. 112-120
-
-
Fisher, B.1
Dignam, J.2
Tan-Chiu, E.3
Anderson, S.4
Fisher, E.R.5
Wittliff, J.L.6
Wolmark, N.7
-
16
-
-
0026747130
-
Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study
-
et al.
-
Ravdin PM, Green S, Dorr TM, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol. 1992; 10: 1284-1291.
-
(1992)
J Clin Oncol.
, vol.10
, pp. 1284-1291
-
-
Ravdin, P.M.1
Green, S.2
Dorr, T.M.3
-
17
-
-
0038688478
-
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases
-
DOI 10.1200/JCO.2003.09.099
-
Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM., Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in 2 large breast cancer databases. J Clin Oncol. 2003; 21: 1973-1979. (Pubitemid 46606386)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.10
, pp. 1973-1979
-
-
Bardou, V.-J.1
Arpino, G.2
Elledge, R.M.3
Osborne, C.K.4
Clark, G.M.5
-
18
-
-
77954526150
-
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer
-
et al.
-
Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28: 2784-2795.
-
(2010)
J Clin Oncol.
, vol.28
, pp. 2784-2795
-
-
Hammond, M.E.1
Hayes, D.F.2
Dowsett, M.3
|